Main Article Content
Our aim was to compare mono polar transurethral resection of the prostate (m-TURP) versus high power diode laser vaporisation of the prostate (DLVP) In terms of efficacy, safety, long term effectiveness, cost analysis and to judge the overall outcome of each modality for treatment of patients with benign prostate hyperplasia (BPH) in a prospective trial.
From December 2015 to November 2017, a total of 50 patients were
included in the cohort study, of whom 25 patients underwent TURP and 25 underwent DLVP. All patients received pre-operative evaluation and followed up at 1, 3, 6 and 12 months postoperatively. Baseline characteristics, perioperative data and postoperative outcomes were compared.
Preoperative data, including age, prostate volume, PSA, IPSS and Q max were similar in the
two groups. Functional outcomes regarding IPSS, Q max and residual urine were significantly improved in both the groups at 1 month postoperatively however no difference in the functional outcome was seen in when both groups were compared with each other. Also, significant difference was seen in operative time, catheter removal time, change in haemoglobin and amount of blood loss in favour of DLVP. There was no statistically significant difference between 1 month post op and further follow up at 3, 6 and 12 months postop in both the groups. DLVP showed less complications as compared to TURP, but it did not reach statistical significance
High power diode laser vaporization of prostate is a feasible procedure in management of benign prostate hyperplasia and is safe, efficacious and a viable alternative to TURP. Only limitation being the cost effectiveness which is poor in comparison to TURP.